BioTech Sector Explorer

Biosimilars are near-identical copies of approved biological medicines (insulin, trastuzumab, adalimumab) made by a different manufacturer after the original patent expires. India dominates this market globally. Biocon Biologics became the first company in the world to have an FDA-approved interchangeable biosimilar insulin (Semglee/Glargine, 2021). The upcoming patent cliff on biologics worth $300B+ in sales creates a decade-long runway.

Monoclonal antibodies are precisely engineered proteins that target specific disease markers — cancer cells, immune signalling molecules, viral proteins. The most profitable class of medicines ever invented. India's ambitions here are primarily in biosimilar mAbs (trastuzumab, bevacizumab), but Biocon and Zydus have novel mAb pipelines. Globally, the field is being transformed by antibody-drug conjugates (ADCs), bispecifics, and AI-designed antibodies.

Contract Development and Manufacturing Organisations (CDMOs) develop and manufacture drugs on behalf of pharma/biotech clients — from molecule discovery to commercial production. CROs (Contract Research Organisations) run clinical trials and pre-clinical studies. India's Syngene (Biocon-listed subsidiary) is the gold standard — running dedicated R&D centres for Bristol Myers Squibb, Amgen, and Baxter. The India CDMO market will be $23.3B by 2026.

Cell therapies (CAR-T, stem cell, NK cell) and gene therapies (AAV vectors, CRISPR, gene editing) represent medicine's most transformative frontier — potentially curing previously incurable genetic diseases and cancers in a single treatment. FDA has approved 20+ CGTs. India's Bharat Biotech launched Nucelion Therapeutics (Nov 2025), a CAR-T CDMO in Hyderabad's Genome Valley. ImmunoACT became the first Indian company to receive CDSCO approval for a domestically developed CAR-T therapy (NexCAR19).

Using genome sequencing to diagnose disease, predict cancer recurrence, guide drug selection (pharmacogenomics), and understand population health. India has unique advantages: South Asia's largest unsequenced population (1.4B people), a distinct genetic disease burden (thalassemia, sickle cell, rare diseases), and rising cancer incidence requiring molecular diagnostics.

Vaccines preventing infectious diseases — from traditional live-attenuated and inactivated vaccines to modern conjugate vaccines, protein subunit vaccines, and emerging mRNA platforms. India is the pharmacy of the world for vaccines: Serum Institute of India (SII) manufactures 1.5 billion doses per year — the largest in the world.

Using machine learning and generative AI to discover new drug molecules, identify novel biological targets, predict clinical trial outcomes, and repurpose existing drugs. Insilico Medicine (HK/US) has an AI-designed drug in Phase II — a world first. In India, Aganitha Cognitive Solutions and Immuneel's AI arm are building platforms.

In-vitro diagnostics (IVD) — blood tests, pathology, imaging — are the backbone of modern medicine. India's diagnostics market is massive but underserved outside metro areas. AI-powered digital pathology and AI-assisted radiology are the next frontier.

Using microorganisms to produce industrial chemicals, enzymes, amino acids, organic acids, and APIs through fermentation. Industrial enzymes (detergents, food processing, textiles) are a $7B global market growing with sustainability mandates.

Engineering biology using DNA design, gene synthesis, and metabolic engineering to create organisms that produce valuable outputs — alternative proteins, biofuels, bioplastics, and biodegradable materials. India's Bangalore cluster is building a synthetic biology ecosystem.

Software platforms that digitise healthcare — Electronic Health Records (EHR), AI-assisted clinical decision support, telemedicine, remote patient monitoring, and health analytics. India's Ayushman Bharat Digital Mission (ABDM) is building a national health ID system for 1.4B people.